Litcius/Paper detail

Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial

Anahita Salehi, Parsa Namaei, Fateme Taghavizanjani, Sayna Bagheri, Kamyar Moradi, Mohammad Reza Khodaie Ardakani, Shahin Akhondzadeh

2022Psychiatry Research24 citationsDOI

Topics & Concepts

RisperidoneExtrapyramidal symptomsTolerabilityPositive and Negative Syndrome ScalePlaceboInternal medicineRandomized controlled trialMedicineScale for the Assessment of Negative SymptomsSchizophrenia (object-oriented programming)Rating scaleClinical trialAntipsychoticPsychiatryBrief Psychiatric Rating ScaleAdverse effectPsychologyPsychosisPathologyDevelopmental psychologyAlternative medicineSchizophrenia research and treatmentCannabis and Cannabinoid ResearchSubstance Abuse Treatment and Outcomes
Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial | Litcius